# Alzheimers Disease Research Foundation

Grantmaking public charity, Wellesley Hills, Massachusetts. EIN 52-2396428.

Source: the foundation’s own IRS returns, read November 21, 2026, as shown by the Alleviate Index. https://sites.alleviate.org/index/funder/alzheimers-disease-research-foundation-522396428

## Applications

Schedule I of Form 990 lists the grants made, not how to apply, so this return does not say whether Alzheimers Disease Research Foundation accepts applications.

## What it gave

- Grants paid: $37,323,497 (Year ending December 2025)
- Grants listed: 161 (To organizations, on that return)
- Typical grant: $201,250 (Half fall between $181,004 and $230,000)

- December 2025: Grants paid $37,323,497; Grants listed 161
- December 2024: Grants paid $28,828,950; Grants listed 106

From Schedule I of its Form 990 returns for the years ending December 2024 to December 2025.

## What it funds, and where

- Focus, by share of linked grant dollars: Health care 81%, Medical research 8%, Animals 4%, Science 3%, Education 2%
- Where it gave, by number of grants: Massachusetts 79, New York 39, California 39, Missouri 35, Texas 11, Maryland 8, Florida 8, Illinois 7, Virginia 7, North Carolina 6, Pennsylvania 5, Michigan 5

## Recent grants to organizations

- [Mass General Brigham Incorporated](https://sites.alleviate.org/index/org/mass-general-brigham-incorporated-041564655) (Somerville, Massachusetts): $1,955,000, year ending December 2025. THE CUREALZ ALZHEIMER'S GENOME PROJECT
- [Mass General Brigham Incorporated](https://sites.alleviate.org/index/org/mass-general-brigham-incorporated-042312909) (Somerville, Massachusetts): $575,000, year ending December 2025. APOE4 ACCELERATES CD8 EXHAUSTION VIA GLUCOCORTICOID SIGNALING IN ALZHEIMER'S FEMALE CARRIERS
- [Mass General Brigham Incorporated](https://sites.alleviate.org/index/org/mass-general-brigham-incorporated-042312909) (Somerville, Massachusetts): $431,250, year ending December 2025. A NEW MODEL OF MICROGLIA GENETIC PERTURBATION IN VIVO TO SCREEN ALL RISK FACTORS ASSOCIATED WITH ALZHEIMER'S DISEASE
- UNIVERSITY OF MICHIGAN (Ann Arbor, Michigan): $402,500, year ending December 2025. NON-INVASIVE MODULATION OF MICROGLIA GENE EXPRESSION USING PERIPHERALLY ADMINISTERED ANTIBODY CONJUGATES
- WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY (New York, New York): $402,500, year ending December 2025. SEX-BIASED TLR7 SIGNALING IN DEMYELINATION AND ITS INHIBITION BY SMALL MOLECULES
- UNIVERSITY OF CALIFORNIA IRVINE (Irvine, California): $402,492, year ending December 2025. PROTEOMIC SIGNATURES OF CEREBROVASCULAR NEUROPATHOLOGY IN DOWN SYNDROME WITH ALZHEIMER DISEASE
- UNIVERSITY OF MICHIGAN (Ann Arbor, Michigan): $398,521, year ending December 2025. UTILIZING HETEROGENEOUS MOUSE MODELS TO DISCOVER MECHANISMS UNDERLYING CALORIC RESTRICTION (CR) ON COGNITIVE OUTCOMES
- WASHINGTON UNIVERSITY IN ST LOUIS (St Louis, Missouri): $345,000, year ending December 2025. APOE CONSORTIUM: INVESTIGATING POTENTIAL CELL AUTONOMOUS NEUROPROTECTION OF APOE PROTECTIVE VARIANTS
- WASHINGTON UNIVERSITY IN ST LOUIS (St Louis, Missouri): $345,000, year ending December 2025. BAC: IDENTIFYING AGE-RELATED PROTEOMIC CHANGES THAT PREDICT FUTURE ONSET OF AMYLOID-BETA AGGREGATION IN ALZHEIMER'S DISEASE
- WASHINGTON UNIVERSITY IN ST LOUIS (St Louis, Missouri): $345,000, year ending December 2025. BEE: MENINGEAL MAST CELL CONTROL OF CSF DYNAMICS IN HOMEOSTASIS AND ALZHEIMER'S DISEASE
- BOSTON CHILDREN'S HOSPITAL (Boston, Massachusetts): $344,528, year ending December 2025. NIC: EFFECTS OF PERIPHERAL INFLAMMATION ON MYELOID CELL FUNCTION IN ALZHEIMER'S DISEASE
- [Mass General Brigham Incorporated](https://sites.alleviate.org/index/org/mass-general-brigham-incorporated-042697981) (Somerville, Massachusetts): $327,501, year ending December 2025. EXPANDING POSTMORTEM BRAIN RESOURCES FOR ALZHEIMER'S DISEASE IN DIVERSE POPULATIONS
- DUKE UNIVERSITY SCHOOL OF MEDICINE (Durham, North Carolina): $320,033, year ending December 2025. UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES
- [Mass General Brigham Incorporated](https://sites.alleviate.org/index/org/mass-general-brigham-incorporated-042697983) (Somerville, Massachusetts): $300,000, year ending December 2025. UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE (Bethesda, Maryland): $287,673, year ending December 2025. BEE: HIGH-RESOLUTION MRI OF THE BRAIN BORDERS
- [Mass General Brigham Incorporated](https://sites.alleviate.org/index/org/mass-general-brigham-incorporated-041564655) (Somerville, Massachusetts): $287,500, year ending December 2025. BEE: HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE (New York, New York): $287,500, year ending December 2025. NIC: ASTROCYTE INFLAMMATORY CONTRIBUTIONS TO AD
- REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO (La Jolla, California): $287,500, year ending December 2025. BEE: HOW DOES VASCULAR FATTY ACID METABOLISM REGULATE THE PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE?
- REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO (La Jolla, California): $287,500, year ending December 2025. NIC: MECHANISMS MEDIATING MICROGLIA SENSING OF PERIPHERAL INFLAMMATION
- STANFORD UNIVERSITY (Redwood City, California): $287,500, year ending December 2025. BAC: CHOROID PLEXUS AGING AND ALZHEIMER'S DISEASE
- UNIVERSITY OF ROCHESTER (Rochester, New York): $287,500, year ending December 2025. BEE: DOES SLYM FAILURE COMPROMISE GLYMPHATIC CLEARANCE IN ALZHEIMER'S DISEASE?
- WASHINGTON UNIVERSITY IN ST LOUIS (St Louis, Missouri): $287,500, year ending December 2025. BAC: BRAIN REGION AND CELL-TYPE SPECIFIC AGING FROM ACCELERATED TO RESILIENT TRAJECTORIES
- WASHINGTON UNIVERSITY IN ST LOUIS (St Louis, Missouri): $287,499, year ending December 2025. BAC: ESTABLISHING ISOGENIC MODELS OF HUMAN NEURON AGING AND PATHWAYS RELEVANT FOR ALZHEIMER'S DISEASE
- UNIVERSITY OF CALIFORNIA IRVINE (Irvine, California): $287,490, year ending December 2025. NIC: EXAMINING THE IMPACT OF PERIPHERALLY DERIVED HUMAN MACROPHAGES IN AD PATHOGENESIS
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY (Cambridge, Massachusetts): $287,477, year ending December 2025. BAC: INVESTIGATING LIPIDOMIC PERTURBATIONS IN THE CSF WITH AGE AND ALZHEIMER'S DISEASE PROGRESSION: TOWARD MECHANISTIC INSIGHTS AND ACCESSIBLE LIPID BIOMARKERS

Method and sources: https://sites.alleviate.org/index/method#funders
